COLLEGIUM PHARMACEUTICAL, INC (COLL): M&A transaction — Collegium closes $525M Ironshore acquisition; adds Jornay PM, boosts 2024 outlook

COLLEGIUM PHARMACEUTICAL, INC

Ironshore acquired for $525M cash plus potential $25M milestone based on Jornay PM 2025 net revenue.
Jornay PM (ADHD) expected >$100M net revenue in 2024; prescriptions grew 32% YoY in H1 2024.
2024 guidance updated: product revenue $620-635M, adjusted EBITDA $395-405M, reflecting four months of Ironshore.
Financed with $200M cash and $325M draw on new $646M term loan; interest rate reduced 300 bps.
Establishes presence in neurology/ADHD; Jornay PM poised as leading growth driver; patents to 2032.

Key facts

Extracted from this filing and checked against the source text.

M&A Transactions SEC 8-K Item 2.01/5.01 confidence 0.9

COLLEGIUM PHARMACEUTICAL, INC completed an acquisition involving Ironshore Therapeutics Inc. for approximately $525 million in cash (closed 2024-09-03).

Action: acquisition
Counterparty: Ironshore Therapeutics Inc.
Consideration: approximately $525 million in cash
Closing: 2024-09-03

Exact text from the filing

The aggregate consideration paid by the Company at the Closing pursuant to the Merger Agreement was approximately $525 million in cash (subject to customary adjustments for net working capital, indebtedness, cash, and transaction expenses), with one potential future commercial milestone payment of $25 million.

View on SEC.gov

31 m&a transactions filed in the last 30 days. Browse all m&a transactions →

COLLEGIUM PHARMACEUTICAL, INC filing history →

Source: SEC EDGAR

accession 0001104659-24-096647

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.